Skip to main content

Active Clinical Trials

For information regarding clinical trials please contact:

Kristy Averette, BSN, RN, CCRP
Research Practice Manager
kristy.averette@duke.edu
Phone: 919-681-5797 

Contact Dr. Jaleel’s office at 919-684-1830 for more information on these studies:

 

  1. Study Title:  A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa: The purpose of this study is to help us understand how safe and effective an investigational drug called bimekizumab (bye-me-key-zoo-mab) is for long-term use in treating hidradenitis suppurativa. Investigational means it is not approved by the US Food and Drug Administration (FDA). This study includes a screening period of up to 5 weeks, a 48-week study drug period, and a safety follow up visit. For the first 16 weeks’ participants will receive either the study drug or placebo. Participants will then receive the study drug for 32 weeks. The drug, bimekizumab, will be given under the skin (subcutaneously) with a needle, and participants will receive two injections of the assigned study drug (bimekizumab or placebo) every two weeks from Week 0 to Week 46. Participants must be at least 18 years old and have had a diagnosis of Hidradenitis Suppurativa for at least 6 months. Further eligibility criteria will be discussed prior to scheduling a screening visit and also during the screening visit.
  2. Study Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults with Moderate-to-Severe Hidradenitis Suppurativa: The purpose of this study is to determine whether LY3041658 can help study participants with moderate-to-severe Hidradenitis Suppurative (HS). LY3041658 is an investigational drug which means the study drug is still being tested in research studies and is not approved by the U.S. Food and Drug Administration (FDA). This study will last for up to 51 weeks which includes a 35-day screening period, 2 study drug periods, and a post-study drug follow-up. During the first study drug period, which will last 16 weeks, participants will receive intravenous (IV) infusions every 2 weeks. Participants will be randomly assigned (like the flip of a coin) to receive either LY3041658 or placebo. During the second study drug period, which will last 20 weeks, participants will receive IV infusions of LY3041658 (600 mg) every 2 weeks. Participants must be at least 18 years old and no older than 65 years. Participants must also have had a diagnosis of Hidradenitis Suppurativa for at least 6 months. Further eligibility criteria will be discussed prior to scheduling a screening visit and also during the screening visit.
  3. Study Title: Role of hormones in hidradenitis suppurativa and other skin diseases: The purpose of this study is to understand how hormones such as sex hormones among others impact skin diseases. This study will include people with a skin condition (such as, hidradenitis suppurativa and/or related conditions such as acne) and healthy people. Participants must be at least 18 years old.
  4. Study Title: Biorepository of Patients with Hidradenitis Suppurativa (HS): Determination of potential predictors and moderators of treatment response in patients with Hidradenitis Suppurativa (HS): The purpose of this study is to collect and maintain information from adults with Hidradenitis Suppurativa, and/or related conditions such as acne, pyoderma gangrenosum, dissecting cellulitis, and pilonidal sinus. This will allow for increased and more focused research on this illness and perhaps eventually lead to the development of improved treatment outcomes. Participants in this study will allow for the past, present and future collection of health, social, clinical and laboratory information pertaining to their Hidradenitis Suppurativa, and/or related conditions such as acne, pyoderma gangrenosum, dissecting cellulitis, and pilonidal sinus. For this study, biospecimens such as blood, urine etc. may be collected during routine visits. Participants will have the option of permitting that specimens such as skin tissue may also be collected. Participants must have a diagnosis of Hidradenitis Suppurativa and must be at least 18 years old.

 

Contact Dr. Cardones' Office at 919-681-8368 for more information on these trials:

1.  Healthy Volunteers, Patients post Hemopoietic Transplantation or Autoimmune and Inflammatory Skin Diseases: Non-invasive cutaneous fibrosis and microvascular imaging in patients who have undergone hemopoietic transplantation (HSCT), patients with autoimmune and inflammatory skin disease, and healthy volunteers

Contact Dr. Murray's Office at 919-684-1830 for more information on this trial:

1. Atopic Dermatitis: A phase 3 pivotal study (118161/118169) and open-label extension (118163) to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects and associated pruritus

Contact Dr. Kheterpal’s office at (919)684-1830 for more information on this trial:

1. Non-Gorlin High Frequency Basal Cell Carcinomas: A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 2 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Patients with Non-Gorlin High Frequency BCC